Aperiomics Selected to Participate at Upcoming Cavendish Global Health Impact Forum

By | 2017-09-21T19:48:56+00:00 May 5th, 2017|

Sterling, VA, May 5, 2017Aperiomics, a biotech company that has created a unique technology to revolutionize the diagnosis of infectious disease, announced today it has been selected to present at the upcoming Cavendish Global Health Impact Forum taking place May 7-9, 2017 in Washington, DC, co-hosted with the Virginia Biotechnology Association (VirginiaBio). The Forum provides an environment for family offices, foundations and impact investors develop and implement their individual pro-social impact investing, grant-giving, and philanthropy programs within health and the life sciences. To accomplish this mission, the Forum showcases presentations and panel discussions by leading family offices, accomplished foundations, impact investors, research institutions, private-sector companies and nonprofit organizations engaged in developing innovations with the potential for transformational impact on disease prevention, diagnosis and treatment. A unique gathering of impact nvestors, Cavendish Impact Forums are hosted by leading institutions around the world and take place four times each year.

Michael Moffat, Cavendish co-founder and Chairman explains, “With the help of our expert advisors, we conduct a global search of research institutions and private-sector companies in order to identify organizations that meet the required standard of excellence. The quality and originality of Aperiomics’ research and scientific insights in the diagnosis of infectious disease positions them to make a major contribution in creating better clinical outcomes, preventing and containing epidemics, and limiting the development of antibiotic-resistant “super bugs”.

“We are honored to be selected to present at this unique event, and it is further recognition of our innovative approach to quickly and accurately identify any known pathogen from a single test. The effects of this novel technology will be felt around the world as health care providers are enabled to quickly diagnose and properly treat diseases afflicting human and animal populations around the world,” said Crystal Icenhour, PhD and CEO of Aperiomics. “We welcome the chance to interact with many of the world’s most accomplished scientists, thought-leaders and generous philanthropic individuals and families who are all dedicated to the common cause of improving the health and lives of people around the world.”

Cavendish Global consists of over 200 leading family offices, foundations and impact investors from around the world with combined assets of over $225 billion who share a passion for pro-social endeavors within health and the life sciences. The Cavendish Global Health Impact Forum provides impact investors with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the information and educational resources required by foundations actively seeking to accelerate technological innovation and health access through sustainable philanthropy, grant-making and impact investing. The Forum is also an opportunity for impact investors to champion and share information on projects and organizations, which they are passionate about with other impact investors from around the world.

 

About Aperiomics

Based in Sterling, VA, Aperiomics was founded in October 2013 as a spinoff from the Computational Biology Institute at George Washington University’s Virginia Science and Technology Campus in Sterling.  The company combines genomics and informatics in an innovative way to produce faster and more accurate results than culture-based or even other molecular-based diagnostic approaches.

From a single test, Aperiomics can simultaneously test for all pathogens whether bacteria, virus, fungus or parasite. The sample can be tissue, plant, animal, or environmental.  Based on its unique process that capitalizes on high-throughput Next-generation sequencing and advanced Bayesian statistics, Aperiomics can not only find a “needle in a haystack” but can also reveal that a “needle” is lurking there – even if it is a formerly unknown pathogen.  This effective system translates into improved human and animal health, reduced risk to public health, and significant health care cost savings.

Further information is available on the Company’s website, www.aperiomics.com.

 

About Cavendish Global

(http://cavendishglobal.com)

Cavendish Global is a peer-to-peer community of paradigm-changing innovators in health and the life sciences; over 200 leading family offices, philanthropists, foundations and impact investors; key opinion leaders and renown institutional partners that share a passion for well-conceived impact investing, sustainable philanthropy and delivering transformative impact. Cavendish provides the resources for innovators to advance their impactful work from mind to marketplace — through connectivity, advisory services, access to key opinion leaders and capital opportunities. Together, the Cavendish community bridges the gaps and accelerates innovation. Cavendish will host Forums in 2017 in Washington, DC, Chicago and Boston.

For more information: http://cavendishglobal.com

 

For Further Information, Contact:

Ian Kenyon

Director, Corporate Communications

Ian.Kenyon@CavendishGlobal.com